Roche to Cochrane critics: Let's compromise on Tamiflu data

Roche ($RHHBY) is making a "fair and transparent" offer to critics at the Cochrane Collaboration: Let's set up an advisory board to review all the data on Tamiflu. As Reuters reports, the proposal is Roche's latest response to calls for open access to data on its flu-fighting drug. That data has become the subject of a heated public debate, as Cochrane researchers took to the pages of the British Medical Journal. Some have even called for a Tamiflu boycott until Roche opens the books. Story


Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.